Relistor approved for opioid-related constipation.
Traynor
Kate
K
D000701:Analgesics, Opioid / Q000009:adverse effects*; D003248:Constipation / Q000188:drug therapy* / Q000209:etiology; D017277:Drug Approval; D006801:Humans; D007279:Injections, Subcutaneous; D009271:Naltrexone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010166:Palliative Care; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors; D014481:United States; D014486:United States Food and Drug Administration
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D000644:Quaternary Ammonium Compounds; D017450:Receptors, Opioid, mu; C032257:methylnaltrexone; D009271:Naltrexone